HEALTHCARE & PHARMACEUTICALS MARKET RESEARCH
Category: News
Latest in the world of healthcare and pharma, brought to you all at one place
-
SII TO SUPPLY 20 CRORE COVAVAX DOSES BY DEC 2021
The Maryland based company, Novavax’s covid-19 vaccine candiate, named Covavax in India is all set to be launched in August-September this year in association with the Pune based Serum Institute of India. The vaccine has shown 90% efficacy in the clinical trials conducted in the U.S. With U.S. easing the availability of the key raw…
-
FIRST DEATH FOLLOWING COVID-19 VACCINATION
A 68 year old man has died after being fully vaccinated with the covishield vaccine in the month of March due to anaphylaxis, which is considered as a severe allergic reaction that could happen post vaccination. In a report submitted by the AEFI Committee, it has been reported that the cause of death is a…
-
HOW LIKELY IS THE THIRD WAVE IN INDIA?
Several speculations are doing the rounds regarding the possibility of a third wave and if children are at a risk of getting infected in the subsequent wave. There is a lot of misinformation involved; however certain things need to be understood and implemented accurately so that we can look towards a foreseeable post pandemic future…
-
Concern of rising SARS-CoV2 Variants and Mutations
As new variants of SARS-Cov2 the official title given to the COVID-19 virus, continue to arise, similar transformations are discovered by the scientists, making the infection more problematic and destructive. This article primarily focuses on those changes called mutations. What happens during mutations? Once a virus gets into our body, it latches onto one of…
-
GOVERNMENT TO RESERVE 30 CRORE DOSES OF BIOLOGICAL E’S NEW VACCINE
Biological E, a Hyderabad-based vaccine and pharmaceutical company, has announced that it has successfully completed the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India called Corbevax and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) – Subject Expert Committee (SEC). The…
-
NEW COVID TREATMENT IN INDIA: ANTIBODY COCKTAIL BY ROCHE AND CIPLA
The monoclonal antibody cocktail, effective against the B.1.617 variant (found in India) is being imported by Roche, a Switzerland-based leading healthcare company and marketed in India through Cipla Ltd has recently received Emergency Use Authorization (EUA) from Central Drug Standard Control Organization (CDSCO) for the treatment of mild to moderate Covid-19 in adults and pediatric…
-
MUCORMYCOSIS(BLACK FUNGUS) : AN EPIDEMIC WITHIN A PANDEMIC
Also known as black fungus, mucormycosis is a rare and invasive systemic fungal infection that occurs due to exposure to mucor mould that may be present in plants, air, soil, animal dung, mucus and nose of people. The mortality rate of black fungus, now declared as a notifiable disease is 50 per cent and with…
-
Everything you should know about 2-DG : DRDO’S exciting new anti-COVID drug
Everything you need to know about 2-DG : DRDO’S new anti-COVID drug
-
NEW AUSTRALIAN COVID VACCINE TO COMPLETELY PREVENT COVID-19 TRANSMISSION
An Adelaide based company, Vaxine Pty Ltd has successfully developed a COVID vaccine, COVAX-19 that holds the ability to completely prevent the covid-19 virus transmission in non-immune individuals. No other vaccine in the world has been yet found to show such promising results. COVAX-19 vaccine is a subunit vaccine based on synthetic protein produced using…
Follow Us
Recent Posts
-
Bedaquiline Role in Treating Tuberculosis having a hefty $1.38 billion dollar market
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
-
Semaglutide’s massive influence on the Diabetes Pharmaceutical Market and 6 competitors
-
FDA approved Leqembi to have $12.9 billion sales
-
Assistive Technology Market; a $82B Growth Story
Tags
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila